UBS Group
BRVE

UBS Group’s Braveheart Bio BRVE Stock Holding History

UBS Group’s Portfolio BRVE Stock Details BRVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.63M Buy
+229,072
New +$6.04M ﹤0.01% 4186

Other funds holding BRVE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Leonard Rickey Investment Advisors
Leonard Rickey Investment Advisors Yakima, Washington $644M AUM 17.66% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

UBS Group's BRVE Position: Q3 2026 in Review

UBS Group opened a new position in Braveheart Bio (BRVE) in Q3 2026: 229,072 shares worth $4.63M. The stake represents ﹤0.01% of the portfolio and ranks #4186 among its holdings.

7 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.

  • UBS Group held 229,072 shares of Braveheart Bio worth $4.63M as of Q3 2026.
  • Braveheart Bio was a new UBS Group position in Q3 2026.
  • Braveheart Bio made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4186 holding.
  • 7 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.